The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and impressive returns is clear, the associated risks are also considerable.… Read More